{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for cortisone root_notes_note in Note (approximate match)
Status:
Investigational
Source:
INN:etimumotide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00099580: Phase 2 Interventional Completed Congestive Heart Failure
(2005)
Source URL:
Class:
PROTEIN
AC-2592 (glucagon-like peptide 1, or GLP-1) was being in development by Amylin Pharmaceuticals for the treatment of severe congestive heart failure. AC-2592 is a glucagon like peptide 1 receptor agonist.
Status:
Investigational
Source:
NCT00259233: Not Applicable Interventional Completed Obesity
(2005)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02383810: Phase 2 Interventional Completed Drug and/or Toxin-induced Diarrhea
(2015)
Source URL:
Class:
PROTEIN
Elsiglutide (ZP 1846) is a synthetic 39-amino acid glucagon-like peptide-2 (GLP-2) analogue. Upon subcutaneous administration, elsiglutide binds to GLP-2 receptors and thereby promotes proliferation of epithelial cells. Elsiglutide prevents or reduces the occurrence of gastrointestinal damage caused by chemotherapeutic agents, including gastrointestinal mucositis and chemotherapy-induced diarrhea (CID). Elsiglutide is being developed by Helsinn Healthcare, for the prevention of chemotherapy-induced diarrhoea.
Status:
Investigational
Source:
NCT03358355: Phase 1/Phase 2 Interventional Completed Peripheral Artery Disease
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03188848: Phase 1 Interventional Unknown status Healthy Subject
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04377126: Phase 2 Interventional Recruiting Peripheral Artery Disease
(2020)
Source URL:
Class:
PROTEIN
Lenomorelin (Ghrelin) is a pleiotropic hormone, whose effect on growth hormone secretion, through the growth hormone secretagogue (GHS) receptor, is one of its many actions. It is synthesized principally in the stomach. Ghrelin-producing cells constitute a distinct group of endocrine cells dispersed throughout the gastric mucosa and to a lesser extent in the small intestine and the endocrine pancreas. Ghrelin plasma levels rise during fasting and chronic caloric restriction to stimulate food intake and fat storage and to prevent life-threatening falls in blood glucose. Plasma ghrelin levels decrease after a meal is consumed and in conditions of energy surplus (such as obesity). Ghrelin has emerged as a key player in the regulation of appetite and energy homeostasis. It stimulates food intake and transduces signals to hypothalamic regulatory nuclei that control energy homeostasis. Ghrelin levels are negatively correlated with body mass index (BMI) and insulin resistance. Lenomorelin is a peptide of 28 amino acids, in which the serine 3 residue is n-octanoylated, which is necessary for biological activity.
Class:
PROTEIN
Aspartocin, an antibiotic, possesses antimicrobial properties
Status:
Investigational
Source:
NCT03427151: Phase 3 Interventional Completed Lupus Erythematosus, Systemic
(2018)
Source URL:
Class:
PROTEIN
Forigerimod (also known as IPP-201101) a phosphopeptide is being investigated for the treatment of Lupus Erythematosus, Systemic. This drug is completed phase III clinical trials and is ready for licensing.
Class:
PROTEIN
Dumorelin is a 27-L-Leu-44a-Gly peptide. It is a stimulator of human growth hormone release.
